Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SonoCloud and Nivolumab in Melanoma Brain Metastases
NCT04021420Phase 2Unknown
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Oct 2019
- Primary completion
- Jan 2022
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of nivolumab in melanoma, sponsored by Assistance publique - Hôpitaux de Paris. Primary endpoint: Most Successful Dose at 6 weeks. Status: unknown.
02
Drugs
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT04021420.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04021420.